Absci Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Stock offerings dilute ownership but raise cash for operations and growth.
Legal document telling investors details about buying shares in the company.
Drug trial progress shows whether the company's medicine is working as hoped.
Board members make important decisions affecting company strategy and success.
Quarterly earnings show if the company is making money or spending it wisely.
Quarterly updates help investors track company progress and pipeline developments.
Year-end financial statements show overall company health and annual performance.
Stocky reads Absci Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Absci Corporation's most recent tracked filing was a 8-K on 24 Jun 2026: Sells 13.5 million shares through underwriters on June 24, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.